VF
VRDN icon

Virtu Financial’s Viridian Therapeutics VRDN Stock Holding History

Virtu Financial’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$748K Buy
38,217
+21,160
+124% +$628K 0.03% 421
2025
Q4 		$531K Buy
+17,057
New +$468K 0.02% 575
2024
Q1 		– Sell
-19,456
Closed -$424K – 2150
2023
Q4 		$424K Buy
+19,456
New +$307K 0.03% 462
2020
Q4 		– Sell
-7,480
Closed -$87K – 1832
2020
Q3 		$87K Buy
+7,480
New +$111K 0.01% 734
2019
Q4 		$25K Buy
+3,432
New +$35.2K ﹤0.01% 1297
2018
Q1 		– Sell
-3,460
Closed -$541K – 2673
2017
Q4 		$541K Buy
3,460
+2,728
+373% +$348K 0.03% 790
2017
Q3 		$100K Buy
+732
New +$123K 0.01% 2078

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Virtu Financial's VRDN Position: Q1 2026 in Review

Virtu Financial increased its Viridian Therapeutics (VRDN) stake by 124% in Q1 2026, buying an estimated $628K and bringing the position to 38,217 shares worth $748K. The position accounts for 0.03% of the portfolio, ranked #421.

Virtu Financial first reported a position in VRDN in Q3 2017 and has held it in 7 quarters since. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Virtu Financial held 38,217 shares of Viridian Therapeutics worth $748K as of Q1 2026.
  • Virtu Financial bought 21,160 Viridian Therapeutics shares in Q1 2026, an estimated $628K.
  • Viridian Therapeutics made up 0.03% of Virtu Financial's portfolio in Q1 2026, its #421 holding.
  • Virtu Financial first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 7 quarters since.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.